Table 4.
Scenario analysis generic pricing imatinib.
| Scenario | A: base-case | B: imatinib 60% of original cost | C: imatinib 40% of original cost | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Cost (US$) | Effectiveness (QALYs) | ICUR (US$/QALY) | Cost (US$) | Effectiveness (QALYs) | ICUR (US$/QALY) | Cost (US$) | Effectiveness (QALYs) | ICUR (US$/QALY) | |
| Chemo | 94,492 | 3.47 | 94,492 | 3.47 | 94,492 | 3.47 | |||
| Imatinib → chemo/SCT | 749,272 | 7.29 | 171,700 | 510,214 | 7.29 | 109,000 | 390,685 | 7.29 | 77,600 |
| Imatinib → nilotinib → chemo/SCT | 965,597 | 8.14 | 253,500 | 726,539 | 8.14 | 253,500 | 607,010 | 8.14 | 253,500 |
| Imatinib → dasatinib → chemo/SCT | 1,099,065 | 8.43 | — | 860,007 | 8.43 | 463,800 | 740,477 | 8.43 | 463,800 |
| Nilotinib → dasatinib → chemo/SCT | 1,200,921 | 8.67 | 445,100 | 1,200,921 | 8.67 | 1,415,200 | 1,200,921 | 8.67 | 1,911,400 |
Chemo: chemotherapy; QALY: quality-adjusted life years; SCT: stem-cell transplantation.